Multimedia

In the final analysis of the ANDROMEDA study, daratumumab added to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for the treatment of AL amyloidosis.

The addition of tafasitimab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.

Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.

According to a prolonged follow-up of the POLARIX trial, treatment with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone showed durable and significant (PFS benefit vs R-CHOP among patients with intermediate-...

According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.

Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to phase 2 study results...

According to data presented at the 66th ASH Annual Meeting by Lucia Masarova, MD, CXCR4-enriched T regulatory cell therapy (CK0804) as an addition to ruxolitinib treatment demonstrated initial safety and promising clinical activity for...

Firas El Chaer, MD, UVA Cancer Center, Charlottesville, Virginia, provides background on a patient with polycythemia vera. In this case, the patient is a 29-year-old with past medical issues of endometriosis and anxiety who was previously...

According to updated results presented by John Burke, MD, at the 66th ASH Annual Meeting, frontline subcutaneous treatment with fixed-duration mosunetuzumab among patients with low-tumor burden FL demonstrated efficacy and safety.

In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.